Artificial heart designer and developer, Carmat, has raised €40.5m (US$43.9m) from the issuance of new shares at €10 per share. It had originally targeted a capital raise of €30m. The company plans to use the funds to ensure the continuity of its activities, to restart the production of its Aeson artificial heart, and ensure the…
Home Healthcare Markets International Business France: Carmat revives production of Aeson artificial heart with new share issue